

Susan Dent

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6790128/susan-dent-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

66
papers

2,070
citations

19
h-index

45
g-index

75
ext. papers

2,931
ext. citations

10.3
avg, IF

4.68
L-index

#	Paper	IF	Citations
66	Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2017 , 35, 893-911	2.2	539
65	Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. <i>Ca-A Cancer Journal for Clinicians</i> , 2016 , 66, 309-25	220.7	287
64	Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 831-41	3.8	146
63	Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis. <i>JAMA Oncology</i> , 2016 , 2, 751-60	13.4	139
62	Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer. <i>Current Oncology</i> , 2015 , 22, 33-48	2.8	81
61	Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011 , 126, 295-310	4.4	72
60	HER2-targeted therapy in breast cancer: a systematic review of neoadjuvant trials. <i>Cancer Treatment Reviews</i> , 2013 , 39, 622-31	14.4	68
59	Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020 , 22, 1966-1983	12.3	61
58	Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years Follow-Up. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1448-1457	2.2	50
57	Population-based assessment of emergency room visits and hospitalizations among women receiving adjuvant chemotherapy for early breast cancer. <i>Journal of Oncology Practice</i> , 2015 , 11, 126-32	3.1	44
56	Gemcitabine in the management of metastatic breast cancer: a systematic review. <i>Breast Cancer Research and Treatment</i> , 2008 , 108, 319-31	4.4	40
55	Optimal systemic therapy for early breast cancer in women: a clinical practice guideline. <i>Current Oncology</i> , 2015 , 22, S67-81	2.8	39
54	Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline. <i>Current Oncology</i> , 2015 , 22, S95-S113	2.8	31
53	Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline. <i>Current Oncology</i> , 2015 , 22, S114-22	2.8	27
52	Risk Model-Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial. <i>JAMA Oncology</i> , 2016 , 2, 225-31	13.4	27
51	Imaging for distant metastases in women with early-stage breast cancer: a population-based cohort study. <i>Cmaj</i> , 2015 , 187, E387-97	3.5	27
50	Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline. <i>Current Oncology</i> , 2015 , 22, S82-94	2.8	25

49	Right heart function deteriorates in breast cancer patients undergoing anthracycline-based chemotherapy. <i>Journal of Animal Science and Technology</i> , 2016 , 3, 79-84	1.6	21
48	Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement.. <i>European Heart Journal</i> , 2021 ,	9.5	21
47	NCIC CTG IND.181: phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies. <i>Investigational New Drugs</i> , 2013 , 31, 1522-9	4.3	18
46	Trastuzumab-induced cardiotoxicity: testing a clinical risk score in a real-world cardio-oncology population. <i>Current Oncology</i> , 2017 , 24, 176-180	2.8	16
45	Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement. <i>Ca-A Cancer Journal for Clinicians</i> , 2020 , 70, 480-504	220.7	16
44	Cardio-Oncology in the Era of the COVID-19 Pandemic and Beyond. <i>Journal of the American Heart Association</i> , 2020 , 9, e017787	6	15
43	Cardio-Oncology Education and Training: JACC Council Perspectives. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 2267-2281	15.1	14
42	A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancer. <i>Current Oncology</i> , 2019 , 26, e70-e80	2.8	13
41	Clinical Experience of Patients Referred to a Multidisciplinary Cardiac Oncology Clinic: An Observational Study. <i>Journal of Oncology</i> , 2015 , 2015, 671232	4.5	12
40	The experience of a multidisciplinary clinic in the management of early-stage breast cancer patients receiving trastuzumab therapy: an observational study. <i>Cardiology Research and Practice</i> , 2012 , 2012, 135819	1.9	12
39	Cardiovascular Manifestations From Therapeutic Radiation: A Multidisciplinary Expert Consensus Statement From the International Cardio-Oncology Society. <i>JACC: CardioOncology</i> , 2021 , 3, 360-380	3.8	12
38	Impact of Stopping Trastuzumab in Early Breast Cancer: A Population-Based Study in Ontario, Canada. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 1222-1230	9.7	11
37	SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumors.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS1119-TPS1119	2.2	11
36	Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis. <i>European Heart Journal</i> , 2021 ,	9.5	11
35	A Phase I Pharmacokinetic Study of Trastuzumab Emtansine (T-DM1) in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function. <i>Clinical Pharmacokinetics</i> , 2017 , 56, 1069-1080	6.2	10
34	Cancer and Cardiovascular Disease: The Complex Labyrinth. <i>Journal of Oncology</i> , 2015 , 2015, 516450	4.5	10
33	Optimizing Cardiovascular Health in Patients With Cancer: A Practical Review of Risk Assessment, Monitoring, and Prevention of Cancer Treatment-Related Cardiovascular Toxicity. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020 , 40, 1-15	7.1	9
32	An International Survey of Health Care Providers Involved in the Management of Cancer Patients Exposed to Cardiotoxic Therapy. <i>Journal of Oncology</i> , 2015 , 2015, 391848	4.5	9

31	Diastolic dysfunction can precede systolic dysfunction on MUGA in cancer patients receiving trastuzumab-based therapy. <i>Nuclear Medicine Communications</i> , 2019 , 40, 22-29	1.6	9
30	Acute cardiogenic shock induced by infusional 5-Fluorouracil. <i>Case Reports in Oncological Medicine</i> , 2014 , 2014, 819396	0.9	8
29	Comparison of Framingham risk score and chest-CT identified coronary artery calcification in breast cancer patients to predict cardiovascular events. <i>International Journal of Cardiology</i> , 2019 , 289, 138-143	3.2	8
28	Strategies to Prevent Cardiovascular Toxicity in Breast Cancer: Is It Ready for Primetime?. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	8
27	Does integration of Magee equations into routine clinical practice affect whether oncologists order the Oncotype DX test? A prospective randomized trial. <i>Journal of Evaluation in Clinical Practice</i> , 2019 , 25, 196-204	2.5	7
26	Investigating the discernible and distinct effects of platinum-based chemotherapy regimens for metastatic triple-negative breast cancer on time to progression. <i>Oncology Letters</i> , 2014 , 7, 866-870	2.6	7
25	Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population. <i>Breast Cancer Research and Treatment</i> , 2021 , 189, 689-699	4.4	7
24	Multiparametric Early Detection and Prediction of Cardiotoxicity Using Myocardial Strain, T1 and T2 Mapping, and Biochemical Markers: A Longitudinal Cardiac Resonance Imaging Study During 2 Years of Follow-Up. <i>Circulation: Cardiovascular Imaging</i> , 2021 , 14, e012459	3.9	6
23	Cardiovascular Care of the Oncology Patient During COVID-19: An Expert Consensus Document From the ACC Cardio-Oncology and Imaging Councils. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 513-522	9.7	6
22	Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer. <i>Current Oncology Reports</i> , 2021 , 23, 128	6.3	6
21	Factors influencing Oncotype DX use in the management of early breast cancer: a single centre experience. <i>European Journal of Cancer</i> , 2014 , 50, 2544-9	7.5	4
20	Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association.. <i>Circulation</i> , 2022 , CIR0000000000001056	16.7	4
19	A phase II study of biweekly pemetrexed and gemcitabine in patients with metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 65, 557-61	3.5	3
18	A phase II study of foretinib in triple-negative, recurrent/metastatic breast cancer: NCIC CTG trial IND.197 (NCT01147484).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1036-1036	2.2	3
17	Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience. <i>Breast Cancer Research and Treatment</i> , 2020 , 184, 733-744	4.4	3
16	Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial. <i>BMJ, The</i> , 2021 , 375, e066588	5.9	3
15	Relationship Between Quality of Life Indicators and Cardiac Status Indicators in Chemotherapy Patients.. <i>Zdravstveno Varstvo</i> , 2021 , 60, 199-209	1.3	2
14	The Role and Impact of Social Media in Cardio-oncology During the COVID-19 Pandemic. <i>Current Oncology Reports</i> , 2021 , 23, 99	6.3	2

13	How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients. <i>Current Oncology</i> , 2021 , 28, 800-812	2.8	2
12	Cardiac Computed Tomography in Cardio-Oncology: Primer.. <i>JACC: CardioOncology</i> , 2021 , 3, 635-649	3.8	2
11	Cardiotoxicities of Modern Treatments in Breast Cancer. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2019 , 21, 34	2.1	1
10	Impact of an electronic tool in prescribing primary prophylaxis with ciprofloxacin or granulocyte colony-stimulating factor for breast cancer patients receiving TC chemotherapy. <i>Supportive Care in Cancer</i> , 2016 , 24, 3185-9	3.9	1
9	A Randomized Trial Comparing 3- versus 4-Monthly Cardiac Monitoring in Patients Receiving Trastuzumab-Based Chemotherapy for Early Breast Cancer.. <i>Current Oncology</i> , 2021 , 28, 5073-5083	2.8	1
8	A randomized, double-blind trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronate in patients with high-risk bone metastases from breast cancer (The Odyssey Study).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 155-155	2.2	1
7	Response: Proposing and Meeting the Need for Interdisciplinary Cardio-Oncology Subspecialty Training by Sherry-Ann Brown, MD, PhD and Nicole Sandhu, MD, PhD. <i>Journal of Cardiac Failure</i> , 2016 , 22, 936	3.3	1
6	Pertuzumab Cardiotoxicity in Patients With HER2-Positive Cancer: A Systematic Review and Meta-analysis.. <i>CJC Open</i> , 2021 , 3, 1372-1382	2	1
5	Duration of Trastuzumab. In matters of the heart, one size may not fit all?. <i>European Journal of Cancer</i> , 2015 , 51, 1657-9	7.5	
4	Trends in systemic management (SM) for the treatment of locally advanced breast cancer: Data from a regional cancer centre. <i>Journal of Clinical Oncology</i> , 2006 , 24, 10728-10728	2.2	
3	Adjuvant trastuzumab (T) in early stage breast cancer (EBC): Is cardiac dysfunction (CD) clinically significant?. <i>Journal of Clinical Oncology</i> , 2007 , 25, 11072-11072	2.2	
2	Does Diastolic Dysfunction Precede Systolic Dysfunction Following Contemporary Breast Cancer Therapy?. <i>JACC: Cardiovascular Imaging</i> , 2020 , 13, 1454-1455	8.4	
1	Validation of heart failure prediction tool in cardio-oncology breast cancer population.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e17693-e17693	2.2	